Kayne Anderson Rudnick Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24	Closed	-$3K	–	705
2022 Q1	$3K	Buy	+24	New	+$2.99K	﹤0.01%	590
2021 Q1	–	Sell	-4	Closed	–	–	754
2020 Q4	$0	Buy	+4	New	+$339	﹤0.01%	735

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's BHVN Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 24 shares — an estimated $3K sold.

Kayne Anderson Rudnick Investment Management first reported a position in BHVN in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Kayne Anderson Rudnick Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Kayne Anderson Rudnick Investment Management sold 24 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $3K.
Kayne Anderson Rudnick Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 2 quarters.
Kayne Anderson Rudnick Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3K in Q1 2022.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.